D. E. Shaw & Co., Inc. Aligos Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $130,698 - $3.39 Million	-123,300 Reduced 79.62%	31,568 $35,000
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $139,461 - $286,969	134,098 Added 645.63%	154,868 $187,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $43,201 - $253,393	20,770 New	20,770 $45,000

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.